Specify a stock or a cryptocurrency in the search bar to get a summary
Oncopeptides AB
ONDOncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company also engages in the research for small popypeptide based killer engages for the treatment of RRMM and hematological or solid tumors; and other peptide-drug conjugates for glioblastoma and hematological or solid tumors. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden Address: Luntmakargatan 46, Stockholm, Sweden, 111 37
Analytics
WallStreet Target Price
63.44 SEKP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures OND
Dividend Analytics OND
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History OND
Stock Valuation OND
Financials OND
Results | 2019 | Dynamics |